KG Jebsen Center for Cancer Immunotherapy NOK 850K annually 2013-2017
Recent publications
Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson Ket al.(2023) Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants NPJ Vaccines, 8(1), 4 DOI 10.1038/s41541-023-00600-6, PubMed 36697432
Sommen SL, Havdal LB, Selvakumar J, Einvik G, Leegaard TM, Lund-Johansen F, Michelsen AE, Mollnes TE, Stiansen-Sonerud T, Tjade T, Wyller VBB, Berven LL(2023) Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19 Front Immunol, 13, 1081718 DOI 10.3389/fimmu.2022.1081718, PubMed 36685555
Meyer S, Blaas I, Bollineni RC, Delic-Sarac M, Tran TT, Knetter C, Dai KZ, Madssen TS, Vaage JT, Gustavsen A, Yang W, Nissen-Meyer LSH, Douvlataniotis K, Laos M, Nielsen MM, Thiede B, Søraas A, Lund-Johansen F, Rustad EH, Olweus J(2023) Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants Cell Rep, 42(1), 111995(in press) DOI 10.1016/j.celrep.2023.111995, PubMed 36656713
Contact information: Group leader Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital, Rikshospitalet, Tel: +47 23073016, E-mail: fridtjof.lund-johansen@rr-research.no